Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
DEA temporarily places mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I, making them illegal to handle without DEA registration.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 24, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Critical. All pharmaceutical manufacturers, API suppliers, contract manufacturers, and compounding outsourcing facilities that handle or intend to handle mitragynine pseudoindoxyl, MGM-15, or MGM-16. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective immediately upon publication in the Federal Register (temporary scheduling is effective for up to two years, with possible extension).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
These substances are now temporarily listed as Schedule I controlled substances, imposing the highest level of regulatory control and prohibiting any unregistered activity.
Who it affects
All pharmaceutical manufacturers, API suppliers, contract manufacturers, and compounding outsourcing facilities that handle or intend to handle mitragynine pseudoindoxyl, MGM-15, or MGM-16.
What you must do
Immediately cease all manufacturing, distribution, or research involving these substances unless you hold a DEA Schedule I registration specifically authorizing such activity. If you have existing stock, contact DEA for disposal guidance.
Deadline
Effective immediately upon publication in the Federal Register (temporary scheduling is effective for up to two years, with possible extension).
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- International Drug Scheduling: Single Convention on Narcotic Drugs, Convention on Psychotropic Substances; Clobromazolam (phenazolam), Cychlorphine (N-propionitrile chlorphine), etc.
- US-CONGRESS BILLS-119hr10133ih: Fair Prescription Pricing Act of 2026
- FDA declares Novo Nordisk plant, key to drug manufacturing for some biotechs, out of compliance - STAT
- Schering-Plough agrees to pay FDA $500 million and bring factories into compliance - American Veterinary Medical Association
- Florida Company Receives FDA Warning Letter - PharmTech.com